Generate Biomedicines’ $400M IPO Puts AI Drug Discovery Back in Focus / OncoDaily
oncodaily - Generate Biomedicines priced its U.S. initial public offering on February 26, 2026, selling 25 million shares at $16 each for gross proceeds of $400 million, with trading expected on the Nasdaq under […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #digitalhealth #healthcarefinance
Friday, February 27, 2026, 11:22 pm / permalink 19912 / 6 stories in 11 days
Novo Nordisk’s CagriSema beaten by Lilly’s Zepbound in head-to-head obesity trial / Endpoints
Elizabeth Cairns / endpoints - Novo Nordisk’s GLP-1/amylin combo drug CagriSema was not as good as Eli Lilly’s marketed obesity shot Zepbound in a head-to-head study, the Danish company said Monday. Patients in the REDEFINE 4 ...
#obesity #healthcare #pharmaceuticals #elililly #novonordisk #weightloss #drugdevelopment
Thursday, February 26, 2026, 7:23 am / permalink 19788 / 12 stories in 13 days
More Research, Less Cancer: £250m raised to transform the future of cancer research / Cancer Research UK
Charlotte Mathé / cancerresearchuk - We’ve reached an incredible moment - £250m raised for our More Research, Less Cancer campaign. This milestone brings us more than halfway to our £400m goal and accelerates our mission to prevent, detect and treat cancer earlier and more effectively. The p…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Tuesday, February 24, 2026, 1:24 pm / permalink 19675 / 53 stories in 14 days
FDA Launches Framework to Accelerate Individualized Therapies for Ultra-Rare Diseases 2026 / OncoDaily
oncodaily - The U.S. Food and Drug Administration (FDA) has released groundbreaking draft guidance introducing a new regulatory framework designed to accelerate the development and approval of individualized therapies for patients with […]
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Tuesday, February 24, 2026, 12:25 pm / permalink 19669 / 6 stories in 14 days
Gilead to acquire cell therapy manufacturer for $7.8B / Beckers
Paige Twenter / beckershospitalreview - In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma. Gilead announced the acquisition agreement a few months after Arcellx published positive…
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #fda #oncology
Monday, February 23, 2026, 4:23 pm / permalink 19605 / 7 stories in 15 days
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in Patients with MIBC Who Are Ineligible for Cisplatin / ESMO
esmo - Findings from the KEYNOTE-905/EV-303 study
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19558 / 15 stories in 16 days
Data and Decisions in Advanced NSCLC at the 2026 TTLC Symposia – IASLC / OncoDaily
oncodaily - International Association for the Study of Lung Cancer (IASLC) shared a post on LinkedIn: “2026 TTLC Symposia Event Data and Decisions in Advanced NSCLC The treatment landscape for advanced NSCLC is evolving […]
#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology
Monday, February 23, 2026, 2:22 am / permalink 19557 / 23 stories in 16 days
A novel C. diff vaccine shows promise / Beckers
Mariah Taylor / beckershospitalreview - Nashville, Tenn.-based Vanderbilt Health researchers have developed a promising novel vaccine to treat Clostridioides difficile infections. Previous vaccine strategies targeted the bacterium’s primary toxins, according to a Feb. 18 system news release. Th…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Saturday, February 21, 2026, 7:21 am / permalink 19520 / 2 stories in 18 days
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront / Endpoints
Kyle LaHucik / endpoints - Novartis will pay $100 million upfront to tap into a macrocyclic peptide platform from Unnatural Products, a deal that could lead to new cardiovascular disease medicines. The move allows the Swiss pharma giant to delve ...
#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment
Saturday, February 21, 2026, 6:22 am / permalink 19517 / 2 stories in 18 days
Disc Medicine Rare Disease Drug Picked for Faster Regulatory Review Is Rejected by the FDA / MedCity
Frank Vinluan / medcitynews - The FDA asked for more data to determine whether Disc Medicine’s bitopertin is benefiting patients with erythropoietic protoporphyria, a rare blood disorder. Analysts say it’s a surprising delay considering bitopertin is one of the first drugs in a new FD…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Saturday, February 21, 2026, 6:22 am / permalink 19516 / 5 stories in 18 days
Walgreens to lay off hundreds of employees / Healthcare Dive
Dani James / healthcaredive - The drugstore retailer said it was simplifying its organization to speed up decision-making in a move impacting at least 600 workers.
#healthcare #pharmaceuticals #mergersandacquisitions
Saturday, February 21, 2026, 12:23 am / permalink 19503 / 2 stories in 18 days
'Universal' nasal-spray vaccine protects against viruses, bacteria and allergens in mice / LiveScience
livescience - In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, scientists report.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #vaccinesafety
Friday, February 20, 2026, 5:22 pm / permalink 19489 / 3 stories in 18 days
Your Cat May Share the Same Cancer Genes as You, and Offer Clues for Treatment / Discover
discovermagazine - Learn how cats and humans can share key cancer mutations — and why those similarities could guide future treatment research.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #oncology
Thursday, February 19, 2026, 9:23 pm / permalink 19449 / 3 stories in 19 days
Immune cells from pediatricians help uncover an antibody cocktail against RSV and hMPV / Medical Express
medicalxpress - Researchers in China recently published a study in Science Translational Medicine describing a new antibody cocktail for protection against two common viruses. The proposed preventative treatment consists of antibodies identified in pediatricians who have…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #infanthealth
Thursday, February 19, 2026, 12:24 pm / permalink 19427 / 3 stories in 19 days
FDA formalizes one pivotal trial policy via NEJM perspective / Endpoints
Zachary Brennan / endpoints - Top FDA officials said that a single pivotal trial requirement will be the “new default standard” for drug approvals, a move that goes beyond the agency’s prior discretion around not requiring two trials. In a ...
#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda
Thursday, February 19, 2026, 11:24 am / permalink 19422 / 3 stories in 19 days
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine / NYT
Christina Jewett and Rebecca Robbins / nytimes - Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda #vaccinesafety
Wednesday, February 18, 2026, 9:23 am / permalink 19353 / 11 stories in 21 days
Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test / MedCity
Frank Vinluan / medcitynews - In the first of two Phase 3 tests, Ocular Therapeutix’s Axpaxli met the main goal of helping maintain vision in patients with the wet form of age-related macular degeneration. The Ocular drug was compared to Eylea, a blockbuster wet AMD drug marketed by R…
#healthcare #pharmaceuticals #biotech #drugdevelopment #fda
Tuesday, February 17, 2026, 9:22 pm / permalink 19334 / 3 stories in 21 days
Lilly appeals retatrutide classification ruling in case that could impact compounders / Endpoints
Alexis Kramer / endpoints - Eli Lilly is challenging a decision over how the FDA classified its experimental, next-gen obesity shot, in a case that could affect the ability of compounders to rival it. On Thursday, Lilly filed a notice ...
#obesity #healthcare #pharmaceuticals #elililly #weightloss #publichealth #drugdevelopment #fda #digitalhealth
Saturday, February 14, 2026, 12:21 pm / permalink 19191 / 15 stories in 24 days
HPV cancer vaccine slows tumor growth and extends survival in preclinical model / Medical Express
medicalxpress - Throughout the past decade, Northwestern University scientists have uncovered a striking principle of vaccine design: Performance depends not only on vaccine components but also on vaccine structure. After proving this concept across multiple studies, the…
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, February 14, 2026, 5:21 am / permalink 19182 / 5 stories in 25 days
Studies test whether gene-editing can fix high cholesterol. For now, take your medicine / Medical Express
medicalxpress - Scientists are testing an entirely new way to fight heart disease: a gene-editing treatment that might offer a one-time fix for high cholesterol.
#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment
Saturday, February 14, 2026, 3:21 am / permalink 19179 / 4 stories in 25 days